HK1068538A1 - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
HK1068538A1
HK1068538A1 HK05100700.6A HK05100700A HK1068538A1 HK 1068538 A1 HK1068538 A1 HK 1068538A1 HK 05100700 A HK05100700 A HK 05100700A HK 1068538 A1 HK1068538 A1 HK 1068538A1
Authority
HK
Hong Kong
Prior art keywords
antiviral compounds
treatment
esters
flaviviruses
hcv
Prior art date
Application number
HK05100700.6A
Other languages
English (en)
Inventor
Albert Stanley Tyms
Debra Lynn Taylor
Original Assignee
Virogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogen Ltd filed Critical Virogen Ltd
Publication of HK1068538A1 publication Critical patent/HK1068538A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
HK05100700.6A 2001-05-03 2005-01-27 Antiviral compounds HK1068538A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110832.3A GB0110832D0 (en) 2001-05-03 2001-05-03 Antiviral compounds
PCT/EP2002/004944 WO2002089780A2 (en) 2001-05-03 2002-05-02 Antiviral compounds

Publications (1)

Publication Number Publication Date
HK1068538A1 true HK1068538A1 (en) 2005-04-29

Family

ID=9913938

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100700.6A HK1068538A1 (en) 2001-05-03 2005-01-27 Antiviral compounds

Country Status (20)

Country Link
US (1) US7601735B2 (no)
EP (1) EP1387681B1 (no)
JP (2) JP2004527566A (no)
KR (1) KR100660241B1 (no)
CN (1) CN100428936C (no)
AT (1) ATE405261T1 (no)
AU (1) AU2002341155B2 (no)
CA (1) CA2445271A1 (no)
CY (1) CY1110437T1 (no)
DE (1) DE60228436D1 (no)
DK (1) DK1387681T3 (no)
ES (1) ES2312587T3 (no)
GB (1) GB0110832D0 (no)
HK (1) HK1068538A1 (no)
IL (2) IL158558A0 (no)
NO (1) NO326292B1 (no)
NZ (1) NZ529448A (no)
PT (1) PT1387681E (no)
WO (1) WO2002089780A2 (no)
ZA (1) ZA200308483B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US20060052414A1 (en) * 2004-08-13 2006-03-09 Migenix, Inc. Compositions and methods for treating or preventing Hepadnaviridae infection
CA2583351A1 (en) * 2004-10-06 2006-04-13 Migenix Inc. Combination anti-viral compositions comprising castanospermine and methods of use
CA2597213A1 (en) * 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
JP2007297289A (ja) * 2006-04-27 2007-11-15 Kitasato Gakuen 抗ウイルス剤
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
KR101314166B1 (ko) * 2011-06-16 2013-10-04 건국대학교 산학협력단 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
BR112015023806A2 (pt) * 2013-03-15 2017-08-22 Watanabe Satoru Novos regimes de dosagem de celgosivir para o tratamento de dengue
EA030695B1 (ru) * 2013-09-27 2018-09-28 Мерк Шарп И Доум Корп. Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
US10046005B2 (en) * 2014-02-07 2018-08-14 Shaker A. Mousa Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201804896QA (en) * 2015-12-11 2018-07-30 60 Pharmaceuticals Llc Novel dosing regimens of celgosivir for the prevention of dengue
SG11201808270PA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
SI3436435T1 (sl) 2016-03-31 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
JP7007290B2 (ja) 2016-04-01 2022-01-24 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドール化合物誘導体
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
IL270727B2 (en) 2017-05-22 2023-03-01 Janssen Pharmaceuticals Inc Transduced indulin derivatives as inhibitors of dengue virus replication
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び／又は予防剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1315276C (en) 1987-07-02 1993-03-30 Paul S. Liu Castanospermine esters and glycosides
US5004746A (en) 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4970317A (en) 1989-08-08 1990-11-13 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine esters
US5066807A (en) 1990-03-12 1991-11-19 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine
US5093501A (en) 1990-03-12 1992-03-03 Merrell Dow Pharmaceuticals Inc. Intermediates in a process for the preparation of castanospermine
GB9027433D0 (en) 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US5959111A (en) 1997-05-22 1999-09-28 Hoechst Marion Roussel, Inc. Process for preparing 6-0-monoesters of castanospermine
KR20010033028A (ko) * 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 막-관련 바이러스 복제의 억제
AU2001234596A1 (en) * 2000-01-28 2001-08-07 Timothy M Block Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Also Published As

Publication number Publication date
JP2004527566A (ja) 2004-09-09
JP4406383B2 (ja) 2010-01-27
EP1387681B1 (en) 2008-08-20
NZ529448A (en) 2005-11-25
CA2445271A1 (en) 2002-11-14
NO326292B1 (no) 2008-11-03
US7601735B2 (en) 2009-10-13
IL158558A0 (en) 2004-05-12
CY1110437T1 (el) 2015-04-29
NO20034878D0 (no) 2003-10-31
DE60228436D1 (de) 2008-10-02
KR20040007527A (ko) 2004-01-24
PT1387681E (pt) 2008-12-02
ZA200308483B (en) 2005-10-26
IL158558A (en) 2011-09-27
CN1516582A (zh) 2004-07-28
CN100428936C (zh) 2008-10-29
WO2002089780A2 (en) 2002-11-14
ES2312587T3 (es) 2009-03-01
EP1387681A2 (en) 2004-02-11
KR100660241B1 (ko) 2006-12-20
NO20034878L (no) 2003-12-22
AU2002341155B2 (en) 2007-10-18
WO2002089780A3 (en) 2003-03-06
ATE405261T1 (de) 2008-09-15
JP2005290015A (ja) 2005-10-20
GB0110832D0 (en) 2001-06-27
US20040147549A1 (en) 2004-07-29
DK1387681T3 (da) 2009-01-05

Similar Documents

Publication Publication Date Title
HK1068538A1 (en) Antiviral compounds
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
SI1404347T1 (sl) 4'-substituirani nukleozidi za zdravljenje bolezni posredovanih z virusom hepatitisa c
RS113904A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MY128463A (en) 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
AU2002360592A8 (en) Inhibitors of hepatitis c virus
EA200701869A1 (ru) Пептидомиметические ингибиторы протеазы
WO2006130627A3 (en) Methods for treating hepatitis c
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
TW200500373A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL376409A1 (en) Composition for the treatment of infection by flaviviridae viruses
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
EA200700718A1 (ru) Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
HK1097467A1 (en) Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
MXPA05008507A (es) Medicamento para enfermedad viral.
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
MXPA05007901A (es) Terapia de combinacion para hcv.
AU2003253894A8 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
TW200513258A (en) Auxiliary agent for hepatitis C
PT1150981E (pt) Composto nucleosidico terapeutico

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220501